tetano
Editor, Senior Moderator
Clin Exp Immunol. 2019 Jun 4. doi: 10.1111/cei.13336. [Epub ahead of print]
[h=1]Acquired immune responses to the seasonal trivalent influenza vaccination in COPD.[/h] Staples KJ[SUP]1,[/SUP][SUP]2[/SUP], Williams NP[SUP]1,[/SUP][SUP]3[/SUP], Bonduelle O[SUP]4,[/SUP][SUP]5[/SUP], Hutton AJ[SUP]4[/SUP], Cellura D[SUP]1[/SUP], Marriott AC[SUP]6[/SUP], Combadi?re B[SUP]4,[/SUP][SUP]5[/SUP], Wilkinson TMA[SUP]1,[/SUP][SUP]2,[/SUP][SUP]3[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] Epidemiological data suggests that influenza vaccination protects against all-cause mortality in COPD patients. However recent work has suggested there is a defect in the ability of some COPD patients to mount an adequate humoral response to influenza vaccination. The aim of our study was to investigate humoral and cell mediated vaccine responses to the seasonal trivalent influenza vaccination (TIV), in COPD subjects and healthy controls. 47 subjects were enrolled into the study; 23 COPD patients, 13 age-matched healthy control (HC - ≥50) and 11 young healthy control subjects (YC - ≤40). Serum and PBMC were isolated pre-TIV vaccination and at days 7, 28 and 6 months post vaccine for Haemagglutinin Inhibition (HAI) titre, antigen-specific T cell and antibody-secreting cell analysis. The kinetics of the vaccine response were similar between YC, HC and COPD patients and there was no significant difference in antibody titres between these groups 28d post-vaccine. As we observed no disease-dependent differences in either humoral or cellular responses, we investigated if there was any association of these measures with age. H1N1 (r=-0.4253, p=0.0036) and Influenza B (r=-0.344, p=0.0192) antibody titre at 28d negatively correlated with age as did H1N1-specific CD4+ T helper cells (r=-0.4276, p=0.0034). These results suggest that age is the primary determinant of response to trivalent vaccine and that COPD is not a driver of deficient responses per se. These data support the continued use of the yearly trivalent vaccine as an adjunct to COPD disease management. This article is protected by copyright. All rights reserved.
This article is protected by copyright. All rights reserved.
[h=4]KEYWORDS:[/h] COPD ; influenza; vaccination
PMID: 31161649 DOI: 10.1111/cei.13336
[h=1]Acquired immune responses to the seasonal trivalent influenza vaccination in COPD.[/h] Staples KJ[SUP]1,[/SUP][SUP]2[/SUP], Williams NP[SUP]1,[/SUP][SUP]3[/SUP], Bonduelle O[SUP]4,[/SUP][SUP]5[/SUP], Hutton AJ[SUP]4[/SUP], Cellura D[SUP]1[/SUP], Marriott AC[SUP]6[/SUP], Combadi?re B[SUP]4,[/SUP][SUP]5[/SUP], Wilkinson TMA[SUP]1,[/SUP][SUP]2,[/SUP][SUP]3[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] Epidemiological data suggests that influenza vaccination protects against all-cause mortality in COPD patients. However recent work has suggested there is a defect in the ability of some COPD patients to mount an adequate humoral response to influenza vaccination. The aim of our study was to investigate humoral and cell mediated vaccine responses to the seasonal trivalent influenza vaccination (TIV), in COPD subjects and healthy controls. 47 subjects were enrolled into the study; 23 COPD patients, 13 age-matched healthy control (HC - ≥50) and 11 young healthy control subjects (YC - ≤40). Serum and PBMC were isolated pre-TIV vaccination and at days 7, 28 and 6 months post vaccine for Haemagglutinin Inhibition (HAI) titre, antigen-specific T cell and antibody-secreting cell analysis. The kinetics of the vaccine response were similar between YC, HC and COPD patients and there was no significant difference in antibody titres between these groups 28d post-vaccine. As we observed no disease-dependent differences in either humoral or cellular responses, we investigated if there was any association of these measures with age. H1N1 (r=-0.4253, p=0.0036) and Influenza B (r=-0.344, p=0.0192) antibody titre at 28d negatively correlated with age as did H1N1-specific CD4+ T helper cells (r=-0.4276, p=0.0034). These results suggest that age is the primary determinant of response to trivalent vaccine and that COPD is not a driver of deficient responses per se. These data support the continued use of the yearly trivalent vaccine as an adjunct to COPD disease management. This article is protected by copyright. All rights reserved.
This article is protected by copyright. All rights reserved.
[h=4]KEYWORDS:[/h] COPD ; influenza; vaccination
PMID: 31161649 DOI: 10.1111/cei.13336